Investigational drug · Phase 2
ILKN421H
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ILKN421H"
First trial start
2026
Jun 29, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ILKN421H", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ILKN421H" as an intervention, largest first.
iLeukon Therapeutics, Inc.Industry
NCT07452224 · 80 participants (planned) · Start Jun 29, 2026 · Primary completion Jun 2029
Drug: ILKN421H; Pembrolizumab · For: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Sites: Los Angeles, California; Fort Worth, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.